Technology

Enabled by the proprietary PurcisionTM technology, LSAMs of pure drug are suspended at time of use and delivered directly to the disease site where the particles are retained as a depot continuously releasing drug molecules as the particles dissolve.

Large Surface Area Microparticles (LSAMs)

  • Intratumoral

  • Peritumoral

  • Intraperitoneal

  • Resection bed

  • Intravesicular

  • Instillation

  • Inhalation

  • Intracystic

  • Topical

Advantages

High sustained local concentration

Continuous tumor kill

Immunogenic effect

Gradual subtoxic clearance

Composition of matter patent on LSAMs protects particle regulatory specifications:

Size

Surface Area

Density

Dissolution

LSAMs are Superior to IV Drugs for Intratumoral Delivery

Taxane Solution for Injection Tumor Site

Paclitaxel or docetaxel injections are designed for IV administration and rapidly diffuse out of the tumor if injected intratumorally.

LSAM-PTX and LSAM-DTX are designed for local administration and become entrapped in the tumor allowing for therapeutic drug release

Tumor tissue concentration of LSAM-PTX and LSAM-DTX versus comparators all given intratumorally in a mouse model

Proprietary PurcisionTM Platform
Large Surface Area Microparticle LSAM Production

API Crystals

  • Large and bulky crystals
  • Large distribution around particle size mean with large clumps
  • Poor uniformity of suspensions
  • Poor drug release due to small surface area
  • Limited to dissolution in solvent as a solution for IV delivery
  • API crystals dissolved in organic solvent and injected into precipitation chamber
  • Sonicated into small uniform droplets via sonic probe
  • Solvent stripped away from droplets via supercritical fluid carbon dioxide
  • Stable microparticles of pure drug precipitated and collected on harvesting filters
  • Platform for multiple drug classes

LSAMs

  • Narrow particle size distribution around mean
  • Microparticles suspended in saline-based fluid for local delivery
  • Excellent suspension uniformity
  • Disproportionately large surface area to particle size ratio allows for:
    • Particle entrapment
    • Therapeutic drug release

Growing Global IP Portfolio
IP Protection Like A New Chemical Entity

References:  NanOlogy internal data, 2015-2022.